Mostrar o rexistro simple do ítem

dc.contributor.authorValdiglesias, Vanessa
dc.contributor.authorSánchez-Flores, María
dc.contributor.authorMarcos-Pérez, Diego
dc.contributor.authorLorenzo-López, Laura
dc.contributor.authorMaseda, Ana
dc.contributor.authorMillán-Calenti, José Carlos
dc.contributor.authorPásaro, Eduardo
dc.contributor.authorLaffon, Blanca
dc.date.accessioned2019-01-30T13:06:04Z
dc.date.issued2018-04-19
dc.identifier.citationValdiglesias V, Sánchez-Flores M, Marcos-Pérez D, et al. Exploring genetic outcomes as frailty biomakers. J Gerontol A Biol Sci Med Sci. 2019; 74(2): 168-175es_ES
dc.identifier.issn1079-5006
dc.identifier.urihttp://hdl.handle.net/2183/21638
dc.description.abstract[Abstract] Frailty has emerged as a reliable measure of the aging process. Because the early detection of frailty is crucial to prevent or even revert it, the use of biomarkers would allow an earlier and more objective identification of frail individuals. To improve the understanding of the biological features associated with frailty as well as to explore different biomarkers for its early identification, several genetic outcomes-mutagenicity, different types of genetic damage, and cellular repair capacity-were analyzed in a population of older adults classified into frail, prefrail, and nonfrail. Besides, influence of clinical parameters-nutritional status and cognitive status-was evaluated. No association of mutation rate or primary DNA damage with frailty was observed. However, DNA repair capacity showed a nonsignificant tendency to decrease with frailty, and persistent levels of phosphorylated H2AX, as indicative of DNA breakage, increased progressively with frailty severity. These results support the possible use of H2AX phosphorylation to provide information regarding frailty severity. Further investigation is necessary to determine the consistency of the current findings in different populations and larger sample sizes, to eventually standardize biomarkers to be used in clinics, and to fully understand the influence of cognitive impairment.es_ES
dc.description.sponsorshipXunta de Galicia; ED431B 2016/013es_ES
dc.description.sponsorshipXunta de Galicia; ED431C 2017/49es_ES
dc.description.sponsorshipXunta de Galicia; IN607C 2016/08es_ES
dc.description.sponsorshipXunta de Galicia; ED481B 2016/190es_ES
dc.description.sponsorshipMinisterio de Economía, Industria y Competitividad (España); RYC-2015–18394es_ES
dc.language.isoenges_ES
dc.publisherOxfordes_ES
dc.relation.urihttps://doi.org/10.1093/gerona/gly085es_ES
dc.rightsThis is the pre-copyedited, author-produced version of an accepted article for publication in The Journals of Gerontology: Series A followinf peer review. The version of record is avaliable online at Oxford Academic web page.es_ES
dc.subjectDNA repaires_ES
dc.subjectγH2AXes_ES
dc.subjectTCR mutationes_ES
dc.titleExploring genetic outcomes as frailty biomakerses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2019-04-19es_ES
dc.date.embargoLift2019-04-19
UDC.journalTitleThe Journals of Gerontology: Series Aes_ES
UDC.volume74es_ES
UDC.issue2es_ES
UDC.startPage168es_ES
UDC.endPage175es_ES


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem